Characteristics | CA-125 level | P-value | |||
---|---|---|---|---|---|
Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | ||
(n = 87) | (n = 90) | (n = 88) | (n = 88) | ||
General clinical characteristics | |||||
Age (years) | 62.23 ± 8.87 | 61.78 ± 9.20 | 60.14 ± 10.58 | 62.08 ± 9.13 | 0.469 |
Sex | Â | Â | Â | Â | 0.957 |
 Male | 51 (58.6) | 51 (56.7) | 48 (54.5) | 49 (55.7) |  |
 Female | 36 (41.4) | 39 (43.3) | 40 (45.5) | 39 (44.3) |  |
BMI (kg/m2) | 24.81 ± 3.10 | 24.86 ± 2.99 | 25.12 ± 3.34 | 24.33 ± 2.93 | 0.395 |
SBP (mmHg) | 127.79 ± 14.82 | 131.12 ± 15.46 | 127.02 ± 16.10 | 126.40 ± 14.89 | 0.170 |
DBP (mmHg) | 78.34 ± 10.61 | 79.82 ± 10.42 | 80.30 ± 9.69 | 78.23 ± 10.61 | 0.443 |
Type of AF | Â | Â | Â | Â | 0.085 |
 Paroxysmal | 69 (79.3) | 64 (71.1) | 68 (77.3) | 56 (63.6) |  |
 Persistent | 18 (20.7) | 26 (28.9) | 20 (22.7) | 32 (36.4) |  |
AF duration (months) | 20.67 ± 43.62 | 21.56 ± 31.52 | 27.66 ± 32.84 | 31.17 ± 37.31 | 0.044 |
CHADS2 score | 0.89 ± 0.81 | 0.82 ± 0.97 | 0.91 ± 0.78 | 1.00 ± 1.12 | 0.587 |
CHA2DS2-VASc score | 1.77 ± 1.15 | 1.66 ± 1.42 | 1.76 ± 1.25 | 1.94 ± 1.61 | 0.629 |
Comorbidity | |||||
Hypertension | 50 (57.5) | 48 (53.3) | 59 (67.0) | 51 (58.0) | 0.299 |
Diabetes | 8 (9.2) | 8 (8.9) | 6 (6.8) | 12 (13.6) | 0.476 |
Dyslipidemia | 3 (3.4) | 1 (1.1) | 7 (8.0) | 7 (8.0) | 0.073 |
Stroke/TIA | 7 (8.0) | 5 (5.6) | 3 (3.4) | 6 (6.8) | 0.606 |
Hematological index | |||||
Hb (g/L) | 137.67 ± 16.81 | 137.87 ± 16.19 | 138.90 ± 15.71 | 140.35 ± 16.18 | 0.681 |
FBG (mmol/L) | 5.00 ± 0.72 | 5.06 ± 0.82 | 5.10 ± 0.87 | 5.15 ± 0.89 | 0.847 |
Scr (μmol/L) | 69.22 ± 13.31 | 71.12 ± 16.23 | 70.38 ± 17.16 | 69.66 ± 15.58 | 0.948 |
UA (μmol/L) | 343.58 ± 72.31 | 333.58 ± 87.98 | 352.57 ± 100.61 | 359.00 ± 89.26 | 0.245 |
ALB (g/L) | 41.83 ± 3.35 | 42.45 ± 2.92 | 42.93 ± 3.27 | 42.09 ± 4.05 | 0.165 |
TC (mmol/L) | 4.27 ± 0.94 | 4.32 ± 0.89 | 4.45 ± 0.93 | 4.58 ± 1.03 | 0.141 |
TG (mmol/L) | 1.56 ± 1.34 | 1.51 ± 0.93 | 1.57 ± 0.71 | 1.85 ± 1.24 | 0.117 |
LDL-C (mmol/L) | 2.47 ± 0.83 | 2.53 ± 0.78 | 2.63 ± 0.82 | 2.60 ± 0.87 | 0.475 |
HDL-C (mmol/L) | 1.16 ± 0.27 | 1.13 ± 0.28 | 1.15 ± 0.28 | 1.15 ± 0.33 | 0.810 |
Echocardiographic parameter | |||||
LAD (mm) | 41.70 ± 4.71 | 42.19 ± 5.67 | 42.22 ± 5.37 | 43.80 ± 6.01 | 0.049 |
LVEF (%) | 63.91 ± 5.58 | 62.62 ± 5.47 | 63.08 ± 5.33 | 61.75 ± 5.41 | 0.068 |
LVD (mm) | 48.71 ± 4.02 | 49.08 ± 4.46 | 48.33 ± 4.08 | 48.76 ± 5.21 | 0.740 |
LVS (mm) | 31.67 ± 3.78 | 32.40 ± 4.32 | 31.74 ± 3.58 | 32.31 ± 4.32 | 0.500 |
Ablation procedure | Â | Â | Â | 0.230 | |
CPVI alone | 58 (66.7) | 59 (65.6) | 64 (72.7) | 51 (58.0) | Â |
CPVI plus additional ablation | 29 (33.3) | 31 (34.4) | 24 (27.3) | 37 (42.0) | Â |
Direct current cardioversion | 22 (25.3) | 26 (28.9) | 26 (29.5) | 29 (33.0) | 0.740 |
Medication | |||||
Oral anticoagulant | Â | Â | Â | 0.999 | |
 Warfarin | 6 (6.9) | 7 (7.8) | 6 (6.8) | 6 (6.8) |  |
 Dabigatran | 63 (72.4) | 65 (72.2) | 65 (73.9) | 62 (70.5) |  |
 Rivaroxaban | 18 (20.7) | 18 (20.0) | 17 (23.3) | 20 (22.7) |  |
ACEI/ARB | 32 (36.8) | 30 (33.3) | 42 (47.7) | 41 (46.6) | 0.132 |
β-blocker | 40 (46.0) | 39 (43.3) | 39 (44.3) | 47 (53.4) | 0.528 |
Amiodarone | 58 (66.7) | 62 (68.9) | 62 (70.5) | 67 (76.1) | 0.557 |
Propafenone | 14 (16.1) | 16 (17.8) | 10 (11.4) | 12 (13.6) | 0.643 |
Biomarker | |||||
hs-CRP (mg/L) | 1.90 ± 1.94 | 1.23 ± 1.26 | 1.88 ± 2.75 | 2.87 ± 3.54 | 0.001 |